<DOC>
	<DOCNO>NCT02639247</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability treatment sofosbuvir/velpatasvir/voxilaprevir ( SOF/VEL/VOX ) fixed-dose combination ( FDC ) 12 week sofosbuvir/velpatasvir ( SOF/VEL ) FDC 12 week direct-acting antiviral ( DAA ) -experienced adult chronic hepatitis C virus ( HCV ) infection without cirrhosis receive prior treatment regimen contain inhibitor HCV NS5A protein .</brief_summary>
	<brief_title>Safety Efficacy SOF/VEL/VOX FDC 12 Weeks SOF/VEL 12 Weeks DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received NS5A Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Willing able provide write informed consent HCV RNA ≥ 10^4 IU/mL screen Chronic HCV infection ( ≥ 6 month ) Treatment experience direct act antiviral medication include NS5A Inhibitor HCV Use protocol specify method contraception Key Current prior history clinically significant illness may interfere participation study Screening ECG clinically significant abnormality Laboratory result outside acceptable range screen Pregnant nursing female Chronic liver disease cause HCV Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Chronic</keyword>
</DOC>